Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)

Clinical Biochemistry

Volumn 47, Issue 1-2, 2014, Pages 132-134

  Bower, Julie K ^a   Pankow, James S ^b   Lazo, Mariana ^c,g   Christenson, Eric ^d   Hoogeveen, Ron C ^e   Ballantyne, Christie M ^e   Halushka, Marc K ^f   Astor, Brad C ^d   Selvin, Elizabeth ^c,g  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Advanced glycation end products; Biological markers; Reliability and validity

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADVANCED GLYCATION END PRODUCTS; BIOLOGICAL MARKERS; RELIABILITY AND VALIDITY;

FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC;

EID: 84890548356     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.11.005     Document Type: Article

References (10)

1. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44(2):129-146.
2. Peppa M., Vlassara H. Advanced glycation end products and diabetic complications: a general overview. Hormones 2005, 4(1):28-37.
3. Vlassara H., Palace M.R. Diabetes and advanced glycation endproducts. J Intern Med 2002, 251(2):87-101.
4. Thornalley P.J. Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)-an introduction. Mol Nutr Food Res 2007, 51(9):1107-1110.
5. Selvin E., Halushka M., Rawlings A., Hoogeveen R.C., Ballantyne C.M., Coresh J., et al. sRAGE and risk of diabetes, cardiovascular disease and death. Diabetes 2013, 62:2116-2121.
6. The ARIC Investigators The Atherosclerosis Risk on Communities (ARIC) study: design and objectives. Am J Epidemiol 1989, 129(4):687-702.
7. Wittwer C., Lehner J., Fersching D., Siegele B., Stoetzer O.J., Holdenrieder S. Methodological and preanalytical evaluation of a RAGE immunoassay. Anticancer Res 2012, 32(5):2075-2078.
8. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25(5):1032-1037.
9. Meigs J.B., Nathan D.M., Cupples L.A., Wilson P.W.F., Singer D.E. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 1996, 49(4):411-417.
10. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114(6):597-605.